Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ImmunoGen revenue
ImmunoGen's revenue is $108.8 million.
What is ImmunoGen's revenue?
- ImmunoGen's revenue growth from 2017 to 2022 is -5.77%.
- ImmunoGen has 75 employees, and the revenue per employee ratio is $1,450,426.
- ImmunoGen's peak quarterly revenue was $113.4M in 2023(q3).
- ImmunoGen peak revenue was $132.3M in 2020.
- ImmunoGen annual revenue for 2021 was 69.9M, -47.2% growth from 2020.
- ImmunoGen annual revenue for 2022 was 108.8M, 55.72% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
ImmunoGen historical revenue
ImmunoGen's peak revenue was $132.3M in 2020. The peak quarterly revenue was $113.4M in 2023(q3).
ImmunoGen's revenue increased from $115.4m in 2017 to $108.8M currently. That's a -5.77% change in annual revenue.
ImmunoGen annual revenue
ImmunoGen annual revenue over time
| Fiscal year / year | ImmunoGen revenue |
|---|---|
| 2017 | $115.4M |
| 2018 | $53.4M |
| 2019 | $82.3M |
| 2020 | $132.3M |
| 2021 | $69.9M |
| 2022 | $108.8M |
Rate ImmunoGen's financial transparency
ImmunoGen annual growth
ImmunoGen saw the greatest revenue growth in 2020, when revenue increased by 60.81%.
ImmunoGen had the lowest revenue growth in 2018, when revenue changed by -53.71%.
ImmunoGen annual growth rate over time
| Year | ImmunoGen growth |
|---|---|
| 2018 | -54%↓ |
| 2019 | 54%↑ |
| 2020 | 61%↑ |
| 2021 | -47%↓ |
| 2022 | 56%↑ |
ImmunoGen quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
ImmunoGen quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2017 | $28.5M | $39.0M | $8.5M | $39.4M |
| 2018 | $19.8M | $9.3M | $10.9M | $13.4M |
| 2019 | $8.6M | $15.5M | $13.3M | $44.9M |
| 2020 | $13.3M | $15.0M | $18.2M | $85.8M |
| 2021 | $15.7M | $16.9M | $9.2M | $28.0M |
| 2022 | $38.1M | $14.2M | $15.4M | $41.2M |
| 2023 | $49.9M | $83.2M | $113.4M | - |
ImmunoGen jobs nearby
Do you work at ImmunoGen?
Did ImmunoGen meet its revenue projections?
ImmunoGen financial information
| CEO | Mark Joseph Enyedy |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 75 |
| Date Founded | 1981 |
| Headquarters | Waltham, Massachusetts |
| Number of Locations | 3 |
| Revenue | $108.8M |
| Net Income | -$222,929,000 |
| Gross Proft | $108.6M (2022) |
| PE Ratio | -2.36 |
| Tax Rate | -0.0% |
| Market Capitalization | $525.0M |
| Total Assets | $348,936,000 |
| Ticker | IMGN |
ImmunoGen jobs you might like
ImmunoGen financing
ImmunoGen received early financing of $2.0M on 2011-06-15.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $2M | 06/2011 |
| Post Ipo Equity | $3M | 10/2011 |
| Post Ipo Equity | $20M | 12/2011 |
| Post Ipo Equity | $30M | 05/2017 |
ImmunoGen investors
| Investors | Security type |
|---|---|
| Eli Lilly and Company | Post Ipo Equity |
ImmunoGen competitors
ImmunoGen's top competitor, Merck, earned an annual revenue of $64.2B.
ImmunoGen's smallest competitor is Immunomedics with revenue of $21.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 311 |
| Merck | $90,328 | $64.2B | 74,000 | 1,432 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Exelixis | $108,978 | $2.2B | 484 | 187 |
| Ariad Pharmaceuticals | $94,078 | $118.8M | 380 | - |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Upsher-Smith Laboratories | $63,937 | $420.0M | 550 | 21 |
| Ligand Pharmaceuticals | $82,001 | $241.5M | 116 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
ImmunoGen highest paying jobs
Zippia gives an in-depth look into the details of ImmunoGen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ImmunoGen. The employee data is based on information from people who have self-reported their past or current employments at ImmunoGen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ImmunoGen. The data presented on this page does not represent the view of ImmunoGen and its employees or that of Zippia.
ImmunoGen may also be known as or be related to IMMUNOGEN INC., ImmunoGen, ImmunoGen Inc, ImmunoGen Inc., ImmunoGen, Inc., Immunogen Inc. and Immunogen, Inc.